Therapeutics in RheumatologyJohn Michael Henderson Moll, Howard Anthony Bird, A. Rushton |
Contents
SECTION II | 181 |
New drugs and experimental progress | 295 |
Clinical applications and implications | 319 |
Copyright | |
7 other sections not shown
Other editions - View all
Common terms and phrases
absorption acid activity acute adverse reactions agents allopurinol analgesic ankylosing spondylitis anti-inflammatory drugs antibody antigen antirheumatic Arthr aspirin assessment associated azapropazone azathioprine blood bone calcium cause cells chloroquine chronic clearance Clin compounds corticosteroids cyclophosphamide cytotoxic disorders diuretics dosage dose drug therapy efficacy enzyme evaluation excretion flurbiprofen function gastrointestinal gold gout half-life hepatic Huskisson hyperuricaemia ibuprofen immune Immunol increased indomethacin inflammation inflammatory inhibition injection interaction intra-articular intravenous joint Lancet levamisole levels liver lupus lymphocyte measures metabolism metabolites methotrexate mg daily naproxen non-steroidal normal NSAIDs occur oral osteoarthrosis osteoporosis pain paracetamol patients with rheumatoid penicillamine pharmacokinetics Pharmacol phenylbutazone piroxicam placebo plasma concentration prednisolone prostaglandin protein binding psoriatic receptors reduced renal reported response Rheum rheumatic diseases rheumatoid arthritis Rheumatol Rheumatology salicylate Scand serum side effects sodium steroids sulindac sulphasalazine symptoms syndrome synovial systemic Ther therapeutic tion tissue toxicity treatment of rheumatoid uricosuric usually vitro warfarin
References to this book
Therapeutic Applications of Nsaids: Subpopulations and New Formulations J. P. Famaey,Harold E. Paulus No preview available - 1992 |